Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event (Details)

v3.5.0.2
Subsequent Event (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May 03, 2016
Apr. 13, 2016
Apr. 30, 2016
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2016
Aug. 31, 2014
Subsequent Event [Line Items]              
Warrants issued is public offering (shares)             3,264,643
Warrant exercise price (USD per share)             $ 125.08
Annual royalty revenue       $ 14,390 $ 10,287    
Corporate Headquarters - La Jolla | Subsequent Event              
Subsequent Event [Line Items]              
Rent expense     $ 51        
Annual increase in rent expense (percent)     3.00%        
Viking Therapeutics, Inc. | Subsequent Event              
Subsequent Event [Line Items]              
Shares issued in public offering (shares)   7,500,000          
Warrants issued is public offering (shares)   7,500,000          
Public offering share price (USD per share)   $ 1.25          
Warrant exercise price (USD per share)   $ 1.50          
Public offering shares purchased by the Company (shares)   560,000          
Public offering warrants purchased by the Company (USD per share)   560,000          
Payments to acquire public offering shares and warrants   $ 700          
Proceeds from collection of note receivable   $ 300          
Shares received for repayment of note receivable (shares)   960,000          
Warrants received for repayment of note receivable (shares)   960,000          
Value of shares and warrants received for repayment of note receivable   $ 1,200          
Ownership percentage in Viking after public offering and repayment of convertible notes   38.00%          
Synthetic Royalties | Subsequent Event              
Subsequent Event [Line Items]              
Payments to Acquire Intangible Assets $ 17,500            
Royalty Agreement, Expiration Period 10 years            
Minimum | Scenario, Forecast | Synthetic Royalties              
Subsequent Event [Line Items]              
Annual royalty revenue           $ 2,750  
Mr. Aryeh, Director | CorMatrix | Subsequent Event              
Subsequent Event [Line Items]              
Equity of CorMatrix beneficially owned by Ligand director     0.56%        
Mr. Knott, Director | CorMatrix | Subsequent Event              
Subsequent Event [Line Items]              
Equity of CorMatrix beneficially owned by Ligand director     0.47%